Methods and apparatuses for monitoring either or both the performance of an orthodontic appliance for repositioning a patient's teeth and/or the user compliance in wearing the appliance using a biosensor. The apparatuses described herein may include one or more sensors, including biosensors, electrical sensors, or both, configured to generate sensor data related to user compliance and/or repositioning of the patient's teeth by an orthodontic appliance.

A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The present invention provides a method for measuring the gastric acidity of a mammal using a .sup.13C-labeled carbonate compound. Specifically, the present invention relates to a method for measuring the gastric acidity of a mammal including the following steps:

(1) using, as a test sample, expired air of a mammalian subject excreted at any point in time within 30 minutes after oral administration of a predetermined amount of a .sup.13C-labeled carbonate compound, measuring behavior of .sup.13CO.sub.2 in the expired air;

(2) comparing the behavior of .sup.13CO.sub.2 (measured .sup.13CO.sub.2 behavior) obtained in step (1) with the behavior of corresponding .sup.13CO.sub.2 (reference .sup.13CO.sub.2 behavior) that has been obtained beforehand in a control mammal; and

(3) determining the gastric acidity of the mammalian subject based on a difference between the reference .sup.13CO.sub.2 behavior and the measured .sup.13CO.sub.2 behavior obtained above.

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

A chemigenetic calcium indicator and a method of measuring calcium are provided. The chemigenetic calcium indicator includes a calcium-binding protein domain attached to a ligand binding protein domain. The method of measuring calcium includes administering a chemigenetic calcium indicator to a subject and determining changes in fluorescence, the chemigenetic calcium indicator including a ligand binding protein domain having a calcium-binding protein domain and a dye-ligand conjugate attached thereto.

Provided is a diagnostic drug for evaluating permeability of intestinal mucosa, including chitin and/or chitosan as a main component. The chitin and/or chitosan to be used preferably has a weight average molecular weight prepared to a range of from 1,000 to 11,600.

The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.

A method and device are provided for evaluating hair growth treatments by applying markers to a hair area at different times to measure pre-treatment hair volume and post-treatment hair volume. By comparing changes in hair volume within one or more hairs, an effectiveness of the hair regrowth treatment can be measured.

The invention relates to the field of imaging, diagnostic, internal vectorized radiotherapy and nuclear medicine. Inventors herein describe new products for use for labelling, detecting and/or imaging angiogenesis, vasculogenesis or a tissue or organ expressing the APJ receptor; for use for detecting, measuring, diagnosing, staging and/or monitoring angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; for use for preventing or treating angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; or for use for evaluating or monitoring the therapeutic effect of an angiogenic or antiangiogenic treatment or of an APJ receptor-targeted treatment. Compositions and kits comprising such products are also herein described as well as uses thereof.